Background
Hyponatremia in cirrhosis is associated with impaired cognition and poor health-related quality of life(HRQOL). However, the benefit of hyponatremia correction is unclear.
Aim
To evaluate the effect of tolvaptan on serum sodium, cognition, HRQOL, companion burden, and brain MRI (volumetrics, spectroscopy and diffusion tensor imaging) in cirrhotics with hyponatremia.
Methods
Cirrhotics with Na<130meq/l were included for a four-week trial. At screening, patients underwent cognitive and HRQOL testing, serum/urine chemistries and companion burden assessment. Patients then underwent fluid restriction and diuretic withdrawal for two weeks after which cognitive tests were repeated. If Na was still<130meq/L, brain MRI was performed & tolvaptan initiated for 14 days with frequent clinical/laboratory monitoring. After 14 days of tolvaptan, all tests were repeated. Comparisons were made between screen, pre and post-drug periods Na, urine/serum laboratories, cognition, HRQOL and companion burden.
Results
24 cirrhotics were enrolled; seven normalized Na without tolvaptan with improvement in cognition. The remaining 17 received tolvaptan of which 14 completed the study over 13±2 days (age 58±6 yrs, MELD 17, 55%HCV, median 26mg/day of tolvaptan). Serum Na and urine free water clearance increased with tolvaptan without changes in mental status or liver function. Cognitive function, HRQOL and companion burden only improved in these 14 patients after tolvaptan, along with reduced total brain and white matter volume, increase in choline on MRS, and reduced cytotoxic edema.
Conclusions
Short-term tolvaptan therapy is well tolerated in cirrhosis. Hyponatremia correction is associated with cognitive, HRQOL, brain MRI and companion burden improvement.